New drug ALC-2203 aims to soothe bronchitis cough
NCT ID NCT07061925
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 2 trial tested whether the experimental drug ALC-2203 can reduce symptoms of acute bronchitis, like cough and chest pain. 169 adults with moderate to severe symptoms took either ALC-2203, an active comparator, or a placebo for 7 days. Researchers measured changes in a symptom score to see if the drug works better than placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALC-2203
- What this could lead to
- If successful, this could lead to a new treatment option to reduce cough and other bronchitis symptoms faster.
- What could go wrong
- This is an early Phase 2 dose-finding trial with only 169 participants, so results may not confirm effectiveness or safety for wider use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE BRONCHITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Konkuk University Medical Center
Seoul, 05030, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug raphamin aims to shorten bronchitis suffering
- New bronchitis drug shows promise in large trial
- 230,000 patient records reveal antibiotic prescribing patterns for lung infections
- Info sheets may curb unnecessary antibiotics for colds and sore throats
- New study aims to curb antibiotic overuse for coughs and colds
- Herbal remedy may speed bronchitis recovery